Impact of blood analysis and immune function on the prognosis of patients with COVID-19

Yue-qiang Fu; Yue-lin Sun; Si-wei Lu; Yang Yang; Yi Wang; Feng Xu

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 16.20067587 doi: medRxiv preprint Overall, 93 persons were treated during the study period, 85 (49 men) of whom met the inclusion criteria for this study ( Table 1 ). The remaining 8 others were excluded due to absence of specific blood test within 12 hours after admission, negative SARS-CoV-2 result of nasopharyngeal swab sample, or death due to advanced age rather than virus infection. The age of the study population was 64.00 (54.50, 70.00) years (range 31-89 y). The interval between symptom onset and admission was 13.00 There was no significant difference in age between the survival and death groups [62.00(55.00, 70.00) y cf. 67.00(50.75, 74.25) y; Table 1 ]. In the death group, the percentage of men (11/14, 78 .6%) and rate of accompanying disease (10/14, 71.4%) were higher compared with the survival group (38/71, 53.52%; and 37/71, 52.11%, respectively), but the differences were not significant. The incidence of dyspnea in the death group was higher than that in the survival group. The survival and death groups were also comparable regarding the interval between onset and admission [13.00 (10.00,15.50) d cf. 12.00 (9.00,15.25) d].